Extracellular Matrix Marker of Arrhythmia Risk (EMMA)

Completed

Conditions studied: Myocardiopathies, Ischemia, Myocardial, Arrythmia, Death, Sudden, Cardiac

In brief

Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.

Key facts

Study ID

NCT00376532

Run by

Thomas Jefferson University

People needed

63

Starts

2006-09-01

Expected to finish

2008-09-01

Last updated by the study team

2014-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• LVEF of ≤ 35% measured within 6 months of ICD implantation
• NYHA class II-IV at the time of ICD implantation
• ICD implantation at least 1 year prior to enrollment

You may not qualify if…

• Status post heart transplant
• Known malignancy in the past 2 years.
• Recent procedure, intervention or surgery within the past 90 days
• Acute MI, CABG, or PTCA/stent within the past 2 months.
• Active rheumatoid arthritis or pulmonary or hepatic fibrosis.
• Taking chronic steroid therapy for a medical condition
• Currently pregnant
• Enrolled in a concurrent study that may confound the results of this study

Where it is running

• Jefferson Heart Institute — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.